In Israel, the primary regulatory authority for health products is the Ministry of Health (MoH), operating through its Pharmaceutical Administration for pharmaceuticals and the Medical Device Division for medical devices and diagnostics. The principal governing legislation includes the Pharmacists Ordinance (1981) and its associated regulations, the Medical Devices Regulations, and the Public Health Ordinance, which together establish the legal framework for registration, approval, and market surveillance of health products. All pharmaceuticals, medical devices, in-vitro diagnostics, and digital health solutions intended for the Israeli market must receive marketing authorization from the MoH before commercialization. The approval process typically involves a formal dossier submission, scientific evaluation, and, for pharmaceuticals, may include a clinical assessment and labeling review. Israel increasingly leverages a reliance pathway, recognizing approvals from stringent regulatory authorities such as the US FDA, EMA, and others to expedite local review.
Key submission requirements include the appointment of a local authorized representative or registered importer, who bears regulatory responsibility for the product in Israel. Pharmaceutical submissions must follow the Common Technical Document (CTD) format and are often supported by reference to approvals from recognized SRAs, significantly streamlining the process under the abbreviated or reliance track. Medical device registrations are aligned with the Global Harmonization Task Force (GHTF) and International Medical Device Regulators Forum (IMDRF) frameworks, and CE marking or FDA clearance can facilitate registration. Notable recent reforms include the digitalization of submission portals, expansion of the SRA reliance framework to cover additional jurisdictions, and increased focus on digital health regulation, with the MoH issuing updated guidance on software as a medical device (SaMD). Israel also participates in international regulatory harmonization initiatives and has adopted risk-based classification systems consistent with global standards.
Public procurement of health products in Israel is centralized and primarily managed through the Ministry of Health, which oversees national health policy and budget allocation for pharmaceuticals, medical devices, and diagnostics used in the public health system. The Israeli healthcare system is structured around four non-profit Health Maintenance Organizations (HMOs), known as Kupot Holim (Clalit, Maccabi, Meuhedet, and Leumit), which are mandated by the National Health Insurance Law (1994) to provide a defined benefits basket, known as the Basket of Health Services. The National Health Council and the Health Technology Assessment (HTA) Committee, operating under the MoH, evaluate new technologies annually during the Basket Update Process, determining which products are reimbursed through the public system. Procurement for hospital-based products occurs through national and institutional tenders, often coordinated by the government-affiliated Memorandum of Procurement bodies and individual hospital procurement departments, with significant price negotiation conducted at the national level.
The private sector plays a meaningful role in the Israeli health market, with supplementary insurance (Mushlam) offered by the HMOs and private commercial insurance providing access to products and services outside the public basket. This dual-channel system creates procurement pathways through private hospitals, out-of-pocket purchases, and supplementary insurance reimbursement. Israel is a high-income country and does not typically rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, which are more relevant to low- and middle-income country contexts. However, Israeli entities are active in global health innovation partnerships and may engage in bilateral research and procurement collaborations. There are no formal local manufacturing preference policies mandating domestic sourcing, but the government supports local MedTech and pharmaceutical innovation through funding bodies such as the Israel Innovation Authority, and locally manufactured products may benefit from streamlined regulatory interactions and government research incentives.
This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.
Generate a free Market Brief for Israel →